Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has unveiled new data demonstrating the efficacy of IMAAVY™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG). Presented at the ...

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

June is the Myasthenia Gravis Month set aside to raise awareness about the breakdown between muscles and the nervous system. A 14-year-old survivor ASAMALA CHAPITA*, who refused to be broken by pain ...

Nausea, vomiting, and fever are extremely common presenting complaints in pre-hospital medicine. They are often symptoms of a minor, self-limiting illness but can also be an early, or only, marker of ...

About Myasthenia Gravis. Myasthenia Gravis (MG) is a rare neurological disorder that severely impairs muscle movement and can lead to life-threatening complications.

Virudhunagar: Nearly 50 people of Kalvimadai village near Narikudi in Virudhunagar took treatment in hospitals on Tuesday morning with symptoms of vom.

Abstract. Background Comorbid autoimmune disorders affect approximately 0.2% of the population.A second autoimmune disease occurs in up to 15% of myasthenia gravis (MG) patients. Objective To evaluate ...

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...

Background Myasthenia Gravis (MG) is an autoimmune disorder presenting with fatigable muscle weakness leading to potential respiratory distress. Clinical management aims to improve patient quality of ...

People with generalized myasthenia gravis (MG) experience psychiatric symptoms including anxiety, depression, and post-traumatic stress disorder (PTSD) at rates higher than that of the general ...

Concluding a recent interview with Jonathan Strober, MD, an investigator on the phase 2/3 Vibrance-MG study (NCT05265273) exploring pediatric use of nipocalimab for generalized myasthenia gravis ...